AvertD is an FDA-cleared artefact - but the investable read-through skews negative
The Opportunity
This is a SHORT proxy call via IHE because the dominant emerging narrative around the blood-based OUD-risk test is controversy and backlash risk rather than clean adoption upside. The mechanism is reputational and policy: even if the intended use is narrow, headline framing can drive payer/clinician behaviour and political scrutiny in ways that are directionally bad for sector sentiment. The signal is contained and the edge comes from the gap between regulatory artefact reality and public interpretation.
The Timing
Freshness is 60 but the oldest claim date detected is 1 December 2023, which tells you this is a resurfacing/renewed debate pattern rather than a brand-new clearance. In a Mixed 58 tape with crosswind 66, expect this to trade like a narrative flare-up: sharp reactions to press coverage, then mean reversion unless payers or health systems move. The confirm trigger is adoption signals (coverage decisions, health-system utilisation); the break trigger is the topic staying in ethics discourse without operational uptake.
The Evidence
The strongest anchor is the FDA device documentation (primary artefact): accessdata.fda.gov . 7.2 also surfaced specialist critique that frames withdrawal calls and utility concerns: statnews.com . Retail/patient community reaction is emotionally intense but treated as colour only for mechanism-risk.